Evotec Adopts ChemAxon's Compliance Checker to Aid Controlled Substance Management

ChemAxon and Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced the licensing and deployment of ChemAxon's Compliance Checker technology and content package to aid in correct handling and storage of chemical compounds used across Evotec's global research sites.

Many countries and regions have regulations about the handling and movement of chemical compounds. Understanding and keeping up to date with regulations is difficult and time consuming, particularly when multiple countries are involved. Compliance Checker is a technology and content package which provides an interface and back end integration tools to help identify, alert and guide the correct handling of controlled substances.

Speaking at the announcement, Alex Drijver, CEO of ChemAxon commented, "We are happy that Evotec have adopted this, given their global reach and wide scope of interests," and added, "we see the functionality as a rational way to automate compliance across our clients' organization."

To find out how Compliance Checker can help you improve your compliance consideration please visit this product page and request a demo.

About ChemAxon
ChemAxon is a leader in providing cheminformatics software platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries.  We focus on active interaction with users and software portability to create powerful, cost effective cross platform solutions that power modern cheminformatics and chemical communication.  The company is privately owned with European headquarters in Budapest, US East Coast headquarters in Cambridge, MA, and sales and support offices in Europe, Japan and acrossNorth America.

About Evotec AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to http://www.evotec.com .

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.